Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
Main Authors: | Shahram Attarian, Peter Young, Thomas H. Brannagan, David Adams, Philip Van Damme, Florian P. Thomas, Carlos Casanovas, Jafar Kafaie, Céline Tard, Maggie C. Walter, Yann Péréon, David Walk, Amro Stino, Marianne de Visser, Camiel Verhamme, Anthony Amato, Gregory Carter, Laurent Magy, Jeffrey M. Statland, Kevin Felice |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-04-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | https://doi.org/10.1186/s13023-024-03110-3 |
Similar Items
-
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
by: Shahram Attarian, et al.
Published: (2021-10-01) -
Structural basis for proapoptotic activation of Bak by the noncanonical BH3-only protein Pxt1.
by: Dahwan Lim, et al.
Published: (2023-06-01) -
Microstructure and Mechanical Properties of 4343/3003/6111/3003 Four-Layer Al Clad Sheets Subjected to Different Conditions
by: Minglong Kang, et al.
Published: (2022-04-01) -
Causes of cracking aluminum 3003 joints by GMAW
by: Eduardo M. Díaz-Cedre, et al.
Published: (2022-01-01) -
Titanium based conversion coatings on aluminium alloy 3003
by: Smit, M, et al.
Published: (1999)